Yangxin Dawayimicol Honey Ointment Improves Cardiac Function in Rats by Regulating VDAC1/NLRP3/Bax/Bcl-2 Pathway
10.13422/j.cnki.syfjx.20250321
- VernacularTitle:养心达瓦依米西克蜜膏通过调节VDAC1/NLRP3/Bax/Bcl-2通路改善大鼠心功能
- Author:
Jingzhuo MA
1
;
Bo YAO
1
;
Hengwen CHEN
1
;
Xuanhui HE
1
Author Information
1. Guang'anmen Hospital， China Academy of Chinese Medical Sciences， Beijing 100053， China
- Publication Type:Journal Article
- Keywords:
Yangxin Dawayimicol honey ointment;
myocardial infarction;
voltage-dependent anion-selective channel 1 （VDAC1）;
nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3 （NLRP3）;
B-cell lymphoma 2 （Bcl-2）;
Bcl-2-associated X protein （Bax）
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2025;31(8):115-124
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the effect and mechanism of Yangxin Dawayimicol honey ointment （YXDW） in improving cardiac function in rats after myocardial infarction. MethodsRats were divided into the sham group， model group， fosinopril sodium tablet group， and YXDW low， medium， and high-dose groups. A rat myocardial infarction model was established by left anterior descending branch ligation. The YXDW groups were administered doses of 0.27， 0.54， and 1.08 g·kg-1·d-1， while the fosinopril sodium tablet group was given 3.60 mg·kg-1·d-1. The sham group and model group were treated with an equal amount of 0.5% sodium carboxymethyl cellulose solution. After continuous gavage for 4 weeks， the effects of YXDW on the signs and cardiac indices of the rats were observed. Echocardiography was used to assess cardiac function， and pathological examination was used to evaluate heart morphology. Enzyme-linked immunosorbent assay （ELISA） was used to assess changes in interleukin-1β （IL-1β）， IL-6， N-terminal pro-brain natriuretic peptide （NT-proBNP）， and tumor necrosis factor-α （TNF-α）. The expression of voltage-dependent anion-selective channel protein 1 （VDAC1）， nucleotide binding oligomerization domain-like receptor family pyrin domain-containing 3 （NLRP3）， B-cell lymphoma -2 （Bcl-2）， and Bcl-2-associated X protein （Bax） was detected by reverse transcription-polymerase chain reaction （Real-time PCR） and Western blot. ResultsThe survival status of rats in all YXDW groups was generally improved. Echocardiographic results showed that， compared to the sham group， the model group exhibited a significant decrease in left ventricular ejection fraction （LVEF） and left ventricular short axis shortening rate （LVFS）， with statistical significance （P<0.01）. Compared to the model group， rats in the treatment groups showed varying degrees of improvement in LVEF and LVFS， with statistical significance （P<0.01）. Pathological examination revealed reduced myocardial cell degeneration， less inflammatory infiltration， intact myofilaments， regular shape， and significantly fewer myocardial fiber disruptions in the treatment groups compared to the model group. Electron microscopy results showed that， compared to the model group， the mitochondria of myocardial cells in the YXDW groups had clear ultrastructure， intact membranes， denser cristae， a clear matrix， and regular arrangement of myofilaments and intercalated discs. ELISA results showed that， compared to the sham group， serum levels of IL-6， IL-1β， and TNF-α were significantly higher in the model group， with statistical significance （P<0.01）. However， in the treatment groups， the serum levels of IL-6， IL-1β， and TNF-α were significantly reduced， with statistical significance （P<0.01）. NT-proBNP levels were significantly higher in the model group compared to the sham group （P<0.01）， but significantly lower in the treatment groups （P<0.01）. Furthermore， Real-time PCR and Western blot results showed that compared to the sham group， the levels of VDAC1， NLRP3， and Bax/Bcl-2 were significantly higher in the model group （P<0.05）. In the treatment groups， these levels were significantly lower than the model group （P<0.05）. ConclusionYXDW significantly improved cardiac function in rats after myocardial infarction. Its mechanism of action may involve the VDAC1/NLRP3/Bax/Bcl-2 pathway to improve mitochondrial structure and function and inhibit the inflammatory response， thereby improving cardiac function.
